Measurement of Antibodies in Adults With a History of Kawasaki Disease

Learn more about:
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Measurement of Antibodies in Adults With a History of Kawasaki Disease

Official Title

Measurement of Antibodies in Adults With a History of Kawasaki Disease

Brief Summary

      Kawasaki disease (KD) is an acute systemic vasculitic syndrome with coronary tropism. It has
      been reported worldwide, but it is ten times more common in Asian population. It is the
      second vasculitis of the child by its frequency after rheumatoid purpura. It occurs in 80% of
      cases between 1 and 5 years, with a maximal incidence around the age of 12 months.

      KD is not well understood and the cause is yet unknown. It may be an autoimmune disorder. The
      problem affects the mucous membranes, lymph nodes, walls of the blood vessels, and the
      heart.The clinical picture of KD associate a persistent fever and an antipyretics resistance
      with mucocutaneous signs and bulky cervical lymphadenopathy usually unilateral.

      There is currently no vaccine available against Kawasaki disease so it is extremely important
      to be able to recognize symptoms before they set in and become too severe.

      Chagas disease (CD) is caused by the parasite Trypanosoma cruzi. Acute CD occurs immediately
      after infection, may last up to a few weeks or months. Infection may be mild or asymptomatic.
      There may be fever or swelling around the site of inoculation, and acute infection may result
      in severe inflammation of the heart muscle. The notion that the pathology of CD has an
      autoimmune component was initially based on the finding of circulating antibodies binding
      heart tissue antigens in patients chronically infected with T. cruzi.

      A recent study reports a possible antigen (non-cruzi-related antibody NCRA) mimicry
      characterized by a serological reactivity to a well-defined T. cruzi antigen in blood samples
      from individuals not exposed to the parasite. The measured seroprevalence of such
      cross-reactivity is in favor of a highly prevalent immunogen acquired in childhood.

      There are similarities in mechanism of CD and KD: it could be interesting to explore the
      presence of NCRA in blood samples from adults with a history of KD.

      The objective of the study is the measurement of the biomarker NCRA in serum in adults with a
      history of KD compare to a control population. This measurement and the prevalence may permit
      to associate the NCRA to a possible pathogenic agent.

Study Type


Primary Outcome

Prevalence of NCRA in the KD population vs control population.


Kawasaki Disease


laboratory biomarker analysis

Study Arms / Comparison Groups

 patients KD
Description:  adults with a history of KD in childhood


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2011

Completion Date

December 2016

Primary Completion Date

December 2015

Eligibility Criteria

        Inclusion Criteria:

          -  History of KD before the age of 18, with or without macroscopic coronary lesions in
             the childhood phase. (KD group only)

          -  18 years old or older at the time of the study.

          -  Agree on participating to all explorations of the study.

          -  Accept genotyping.

          -  Absence of cardiovascular risk factors

        Exclusion Criteria:

          -  - Atypical KD (KD group only)

          -  Documented or suspected coronary ischemia,

          -  Refusal to participate to the study or sign the consent

          -  Contra-indication to the injection of iodinated contrast agents (allergy, renal

          -  Hypersensitivity to dobutamine,

          -  No effective contraception method for females with child bearing potential,

          -  Breastfeeding, or pregnant females,

          -  Treatment modifying endothelial reactivity

          -  History of severe intolerance to iodinated contrast agents,

          -  Subjects who can't hold their breath for at least 20 seconds,

          -  Irregular or absence of sinus rhythm, especially atrial or ventricular arrhythmia

          -  Unability to give information to the subject,

          -  No coverage from a Social Security system

          -  Deprivation of civil rights




18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


François Gueyffier, Pr, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Hospices Civils de Lyon

Study Sponsor

François Gueyffier, Pr, Principal Investigator, Hospices Civils de Lyon

Verification Date

July 2016